Bristol-myers Squibb Compnay

Universitéde Montreal

Samuel Kaye Reznik

Eldon Scott Priestley

Xiaojun Zhang

Jeremy M Richter

Oz Scott Halpern

Wen Jiang

Edward H Ruediger

Wu Yang

Rejean Ruel

Sasmita Tripathy

Qinghong Fu

J Alex Bates

Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein Ris a bicyclic heteroaryl group substituted with zero to 3 R; and R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Bicyclic heteroaryl substituted compounds

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or β-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Biarylmethyl heterocycles

Disclosed are compounds of Formula (I) to (VIII): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof, wherein Ris a tricyclic heteroaryl group substituted with Rand zero to 2 R; and R, R, R, R, R, and n are defined herein. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder.

Tricyclic heteroaryl-substituted quinoline and azaquinoline compounds as PAR4 inhibitors

The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are biased agonists, or &#x3b2;-Arrestin agonists of the angiotensin II receptor, which may be used as medicaments.

Disclosed are compounds of Formula (I) to (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. 

Growing community of inventors

Brookline, MA, United States of America

Samuel Kaye Reznik